{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:20:08Z","timestamp":1787062808366,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126539","type":"journal-article","created":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T15:04:06Z","timestamp":1732979046000},"page":"126539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11\u00a0years in Ontario: A Canadian immunization research network (CIRN) study"],"prefix":"10.1016","volume":"44","author":[{"given":"Pierre-Philippe","family":"Pich\u00e9-Renaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha S.M.","family":"Drover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun K.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"Buchan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharifa","family":"Nasreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Tadrous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Thampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumanan","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Guttmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0005","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1503\/cmaj.221726","article-title":"Acute health care use among children during the first 2.5 years of the COVID-19 pandemic in Ontario, Canada: a population-based repeated cross-sectional study","volume":"196","author":"Iskander","year":"2024","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246326","article-title":"The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: a systematic review of fatality and ICU admission in children worldwide","volume":"16","author":"Kitano","year":"2021","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126539_bb0015","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jamapediatrics.2023.2357","article-title":"Pediatric hospitalizations and ICU admissions due to COVID-19 and pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 in England","volume":"177","author":"Ward","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0020","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1093\/cid\/ciac275","article-title":"Coronavirus disease 2019 disease severity in children infected with the omicron variant","volume":"75","author":"Butt","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"13","key":"10.1016\/j.vaccine.2024.126539_bb0025","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2022.2274","article-title":"Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada","volume":"327","author":"Ulloa","year":"2022","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126539_bb0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2352-4642(22)00027-X","article-title":"Paediatric hospitalisations due to COVID-19 during the first SARS-CoV-2 omicron (B.1.1.529) variant wave in South Africa: a multicentre observational study","volume":"6","author":"Cloete","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.vaccine.2024.126539_bb0035","series-title":"COVID-19 vaccines for children 5 to 11 years ofage","author":"Public Health Ontario","year":"2022"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126539_bb0040","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.vaccine.2024.03.075","article-title":"Effectiveness of COVID-19 vaccination against school absenteeism in children and adolescents hospitalized with COVID-19","volume":"42","author":"Maltezou","year":"2024","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126539_bb0045","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-060302","article-title":"A new definition for multisystem inflammatory syndrome in children","volume":"151","author":"Son","year":"2023","journal-title":"Pediatrics"},{"issue":"32","key":"10.1016\/j.vaccine.2024.126539_bb0050","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.15585\/mmwr.mm6932e2","article-title":"COVID-19-associated multisystem inflammatory syndrome in children - United States, march-July 2020","volume":"69","author":"Godfred-Cato","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126539_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S2352-4642(22)00100-6","article-title":"Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a danish nationwide prospective cohort study","volume":"6","author":"Nygaard","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126539_bb0060","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jama.2021.23262","article-title":"Multisystem inflammatory syndrome in children by COVID-19 vaccination status of adolescents in France","volume":"327","author":"Levy","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126539_bb0065","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1093\/cid\/ciac553","article-title":"Evelina paediatric inflammatory multisystem syndrome temporally related to S-C-SG. Lower risk of multisystem inflammatory syndrome in children with the delta and omicron variants of severe acute respiratory syndrome coronavirus 2","volume":"76","author":"Cohen","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126539_bb0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapediatrics.2022.2206","article-title":"Risk and phenotype of multisystem inflammatory syndrome in vaccinated and unvaccinated danish children before and during the omicron wave","volume":"176","author":"Holm","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0075","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12969-023-00848-1","article-title":"The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis","volume":"21","author":"Hamad Saied","year":"2023","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126539_bb0080","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15585\/mmwr.mm7310a2","article-title":"Notes from the field: surveillance for multisystem inflammatory syndrome in children - United States, 2023","volume":"73","author":"Yousaf","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126539_bb0085","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1097\/INF.0000000000004103","article-title":"Multisystem inflammatory syndrome in children among persons who completed a two-dose COVID-19 vaccine primary series compared with those reporting no COVID-19 vaccination, US national MIS-C surveillance","volume":"42","author":"Yousaf","year":"2023","journal-title":"Pediatr Infect Dis J"},{"issue":"24","key":"10.1016\/j.vaccine.2024.126539_bb0090","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1001\/jama.2022.8025","article-title":"Severity and incidence of multisystem inflammatory syndrome in children during 3 SARS-CoV-2 pandemic waves in Israel","volume":"327","author":"Levy","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2024.126539_bb0095","series-title":"Evaluation of COVID-19 vaccine effectiveness: interim guidance","author":"World Health Organization (WHO)","year":"2024"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126539_bb0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies conducted using observational routinely-collected health data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126539_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040296","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"4","author":"von Elm","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2024.126539_bb0110","series-title":"Effectiveness of COVID-19 vaccines against omicron or delta infection","author":"Buchan","year":"2022"},{"key":"10.1016\/j.vaccine.2024.126539_bb0115","article-title":"Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study","volume":"374","author":"Chung","year":"2021","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126539_bb0120","first-page":"1682","article-title":"Pivoting data and analytic capacity to support Ontario\u2019s COVID-19 response","volume":"5","author":"Chung","year":"2020","journal-title":"Int J Popul Data Sci"},{"key":"10.1016\/j.vaccine.2024.126539_bb0125","series-title":"Effectiveness of a fourth dose of COVID-19 vaccine among long-term care residents in Ontario, Canada: Test-negative design study","author":"Grewal","year":"2022"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126539_bb0130","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41564-021-01053-0","article-title":"Effectiveness of COVID-19 vaccines against symptomatic SARS-CoV-2 infection and severe outcomes with variants of concern in Ontario","volume":"7","author":"Nasreen","year":"2022","journal-title":"Nat Microbiol"},{"issue":"31","key":"10.1016\/j.vaccine.2024.126539_bb0135","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1016\/j.vaccine.2019.06.011","article-title":"Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the flu and other respiratory viruses research (FOREVER) cohort","volume":"37","author":"Kwong","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126539_bb0140","series-title":"The Johns hopkins ACG system","author":"Johns Hopkins University","year":"2023"},{"key":"10.1016\/j.vaccine.2024.126539_bb0145","series-title":"Canadian coding standardsfor version 2022 ICD-10-CA and CCI. Addendum: Pandemicsand epidemics (COVID-19)","author":"Canadian Institute for Health Information","year":"2022"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-057838","article-title":"Validity of ICD-10 codes for COVID-19 patients with hospital admissions or ED visits in Canada: a retrospective cohort study","volume":"12","author":"Wu","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2024.126539_bb0155","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268822000024","article-title":"Identification and description of patients with multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection using the premier healthcare database","volume":"150","author":"DeCuir","year":"2022","journal-title":"Epidemiol Infect"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.49552","article-title":"Disparities in multisystem inflammatory syndrome in children and COVID-19 across the organ dysfunction continuum","volume":"6","author":"Martin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.126539_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.107084","article-title":"Multisystem inflammatory syndrome in adults: comparison with other inflammatory conditions during the Covid-19 pandemic","volume":"206","author":"Auger","year":"2023","journal-title":"Respir Med"},{"issue":"21","key":"10.1016\/j.vaccine.2024.126539_bb0170","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1016\/j.vaccine.2023.04.007","article-title":"Methodological changes implemented over time to support accurate and timely COVID-19 vaccine coverage estimates: Ontario, Canada","volume":"41","author":"Leigh Hobbs","year":"2023","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0175","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2024.126539_bb0180","series-title":"Ontario\u2019s COVID-19 vaccination plan","author":"Ontario Ministry of Health","year":"2023"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126539_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.11182","article-title":"Underlying medical conditions associated with severe COVID-19 illness among children","volume":"4","author":"Kompaniyets","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2024.126539_bb0190","series-title":"COVID-19 vaccine uptake and intent: Canadian community health survey (CCHS) insight","author":"Public Health Agency of Canada","year":"2023"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126539_bb0195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S2352-4642(23)00078-0","article-title":"Safety and effectiveness of vaccines against COVID-19 in children aged 5-11 years: a systematic review and meta-analysis","volume":"7","author":"Piechotta","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126539_bb0200","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2022-059513","article-title":"COVID-19 vaccine effectiveness against omicron infection and hospitalization","volume":"151","author":"Piche-Renaud","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.126539_bb0205","article-title":"Risk factors for severe COVID-19 in hospitalized children in Canada: a national prospective study from march 2020-may 2021","volume":"15","author":"Farrar","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126539_bb0210","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-053418","article-title":"Risk factors for severe COVID-19 in children","volume":"149","author":"Woodruff","year":"2022","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126539_bb0215","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/cid\/ciac637","article-title":"BNT162b2 mRNA vaccination against coronavirus disease 2019 is associated with a decreased likelihood of multisystem inflammatory syndrome in children aged 5-18 years-United States, July 2021 - April 2022","volume":"76","author":"Zambrano","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2024.126539_bb0220","article-title":"Risk factors for multisystem inflammatory syndrome in children - a population-based cohort study of over 2 million children","volume":"19","author":"Rhedin","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2024.126539_bb0225","article-title":"Lower risk of multi-system inflammatory syndrome in children (MIS-C) with the omicron variant","volume":"27","author":"Lopez","year":"2022","journal-title":"Lancet Reg Health West Pac"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126539_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12080997","article-title":"Exploring factors influencing changes in incidence and severity of multisystem inflammatory syndrome in children","volume":"12","author":"Castaldo","year":"2023","journal-title":"Pathogens"},{"issue":"6","key":"10.1016\/j.vaccine.2024.126539_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065711","article-title":"Immunology of multisystem inflammatory syndrome after COVID-19 in children: a review of the current evidence","volume":"24","author":"Filippatos","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126539_bb0240","doi-asserted-by":"crossref","first-page":"422","DOI":"10.15585\/mmwr.mm7111e1","article-title":"Effectiveness of 2-dose BNT162b2 (Pfizer BioNTech) mRNA vaccine in preventing SARS-CoV-2 infection among children aged 5-11 years and adolescents aged 12-15 years - protect cohort, july 2021-february 2022","volume":"71","author":"Fowlkes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126539_bb0245","doi-asserted-by":"crossref","first-page":"352","DOI":"10.15585\/mmwr.mm7109e3","volume":"71","author":"Klein","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"20","key":"10.1016\/j.vaccine.2024.126539_bb0250","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa2202826","article-title":"BNT162b2 protection against the omicron variant in children and adolescents","volume":"386","author":"Price","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T14:47:32Z","timestamp":1735656452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"alternative-id":["S0264410X24012210"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126539","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine effectiveness against severe omicron-related outcomes in children aged 5 to 11\u00a0years in Ontario: A Canadian immunization research network (CIRN) study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126539"}}